S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer

• Main Authors: Zhenyan Hou (Author), Songwen Lin (Author), Tingting Du (Author), Mingjin Wang (Author), Weida Wang (Author), Shen You (Author), Nina Xue (Author), Yichen Liu (Author), Ming Ji (Author), Heng Xu (Author), Xiaoguang Chen (Author)
• Format: Book
• Published: MDPI AG, 2023-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Microtubule-targeting agents are widely used as active anticancer drugs. However, drug resistance always emerges after their long-term use, especially in the case of paclitaxel, which is the cornerstone of all subtypes of breast cancer treatment. Hence, the development of novel agents to overcome th...